BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 2824611)

  • 1. Lysis of human T cell leukemia virus infected T and B lymphoid cells by interleukin 2-activated killer cells.
    Froelich CJ; Guiffaut S
    J Immunol; 1987 Dec; 139(11):3637-43. PubMed ID: 2824611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells.
    Ruscetti FW; Mikovits JA; Kalyanaraman VS; Overton R; Stevenson H; Stromberg K; Herberman RB; Farrar WL; Ortaldo JR
    J Immunol; 1986 May; 136(10):3619-24. PubMed ID: 2422259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells.
    Burns GF; Triglia T; Werkmeister JA
    J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of human T-lymphotropic virus type-1 (HTLV-1)-infected cell line MT-2, which is not killed by a natural killer cell line NK-92 but is killed by lymphokine-activated killer cells.
    Komatsu F; Yoshida S
    Oncol Res; 1999; 11(5):213-8. PubMed ID: 10608615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infection of human natural killer (NK) cells with replication-defective human T cell leukemia virus type I provirus. Increased proliferative capacity and prolonged survival of functionally competent NK cells.
    Lo KM; Vivier E; Rochet N; Dehni G; Levine H; Haseltine WA; Anderson P
    J Immunol; 1992 Dec; 149(12):4101-8. PubMed ID: 1460293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.
    Damle NK; Doyle LV; Bradley EC
    J Immunol; 1986 Nov; 137(9):2814-22. PubMed ID: 2944965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals.
    Robertson MJ; Cameron C; Lazo S; Cochran KJ; Voss SD; Ritz J
    Nat Immun; 1996-1997; 15(5):213-26. PubMed ID: 9390270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
    Itoh K; Tilden AB; Kumagai K; Balch CM
    J Immunol; 1985 Feb; 134(2):802-7. PubMed ID: 3917475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells.
    Hagihara M; Gansuvd B; Ueda Y; Tsuchiya T; Masui A; Tazume K; Inoue H; Kato S; Hotta T
    Cancer Immunol Immunother; 2002 Mar; 51(1):1-8. PubMed ID: 11845254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial activation of human natural killer cells. Characteristics of the activation process and identification of the effector cell.
    Tarkkanen J; Saksela E; Lanier LL
    J Immunol; 1986 Oct; 137(8):2428-33. PubMed ID: 3093576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytolysis of mammary tumor targets by resting, interleukin-2 stimulated and in vitro cultured peripheral blood lymphocytes from breast cancer patients.
    Brenner BG; McCrea EL; Margolese RG
    Anticancer Res; 1988; 8(4):653-8. PubMed ID: 3263077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
    Xun CQ; Thompson JS; Jennings CD; Brown SA
    Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
    Kaufmann Y; Levanon M; Davidsohn J; Ramot B
    J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection.
    Yanagisawa M; Kato M; Ikeno K; Kobayashi T; Miyagawa Y; Komiyama A; Akabane T
    Clin Exp Immunol; 1987 May; 68(2):251-8. PubMed ID: 2820633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.